Next Generation Delivery System (NGDS) for SBRT in thorax and upper abdomen

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective, multi-center study evaluates the Next Generation Delivery System (NGDS) as a breath-hold workflow for delivering stereotactic body radiotherapy. Participants will have SBRT planned with breath hold on a conventional accelerator and will undergo a mock treatment on NGDS to gather setup and alignment images. The trial aims to determine if NGDS can shorten treatment times and improve patient tolerance with less need for breath holding. ENROLLED participants will be adults with thoracic or upper abdominal targets and good performance status undergoing SBRT as part of routine care. The study is conducted at Siteman Cancer Center and University Hospitals Cleveland Medical Center under Varian as lead sponsor.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Target lesions in the thorax or upper abdomen
2. Planned to undergo SBRT radiation treatment delivered on a conventional "C-arm" or ring gantry CBCT guided linear accelerator under breath hold conditions
3. ECOG performance status 0-1
4. At least 21 years of age
5. Able to sign informed consent

Exclusion Criteria:

1. Participants enrolled in another clinical investigation the investigator believes to be in conflict with this clinical investigation.
2. Participants with any other medical condition or laboratory value that would, at the discretion of the investigator, preclude the patient from participation in this clinical investigation.

Where it's running

• Siteman Cancer Center Washington University
  St Louis, Missouri, United States Recruiting
• University Hospital Cleveland Medical Center
  Cleveland, Ohio, United States Recruiting

Study contacts

• Study coordinator: Jennifer Woo
• Email: jennifer.woo@siemens-healthineers.com
• Phone: 437-991-3496

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Boosting lung cancer screening for patients seen in the emergency department

  This project will test whether giving eligible emergency department patients a facilitated referral plus text reminders helps more people get lung cancer screening.

  Recruiting University of Rochester · Rochester, New York · NCT07287085

• Integrated genomic and clinical database for cancer biomarker discovery

  Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.

  Recruiting Samsung Medical Center · Seoul, Gang-Nam · NCT07911267

• Using contrast-enhanced ultrasound to check for local pancreatic cancer recurrence after surgery

  This pilot test uses contrast-enhanced ultrasound to see if it can help detect return of pancreatic cancer after surgery in patients being watched with CT scans.

  Recruiting Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07910383

• Combination of ivermectin with standard skin-protective care for daraxonrasib-related skin toxicity in pancreatic cancer

  This study tests whether adding ivermectin to standard preventive skin care helps people with pancreatic cancer who develop skin side effects from daraxonrasib.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07895498

• Becotatug Vedotin Plus Anti-PD-1 and S-1 in EGFR-Positive Advanced Pancreatic Cancer

  This study tests a three-drug regimen (becotatug vedotin, an anti-PD-1 therapy, and S-1) in adults with EGFR-positive advanced pancreatic cancer who have not responded to at least one prior therapy.

  Recruiting Ningbo Medical Center Lihuili Hospital · Ningbo, Zhejiang · NCT07892573

• Blood protein biomarkers to help diagnose pancreatic cancer in adults

  This study tests whether blood protein biomarkers can help detect pancreatic ductal adenocarcinoma and tell it apart from chronic pancreatitis and mucinous pancreatic lesions, and whether combining markers with CA 19-9 improves accuracy.

  Recruiting Grigore T. Popa University of Medicine and Pharmacy · Iași · NCT07875582

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.